Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Restructuring Costs (2016 - 2020)

Tg Therapeutics (TGTX) has 5 years of Restructuring Costs data on record, last reported at $16.2 million in Q4 2020.

  • For Q4 2020, Restructuring Costs rose 452.51% year-over-year to $16.2 million; the TTM value through Dec 2020 reached $41.5 million, up 336.9%, while the annual FY2020 figure was $41.5 million, 336.9% up from the prior year.
  • Restructuring Costs reached $16.2 million in Q4 2020 per TGTX's latest filing, up from $11.6 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $16.2 million in Q4 2020 and bottomed at $1.1 million in Q1 2016.
  • Average Restructuring Costs over 5 years is $3.5 million, with a median of $1.9 million recorded in 2018.
  • Peak YoY movement for Restructuring Costs: decreased 8.02% in 2019, then soared 452.51% in 2020.
  • A 5-year view of Restructuring Costs shows it stood at $1.3 million in 2016, then surged by 33.55% to $1.8 million in 2017, then fell by 6.0% to $1.7 million in 2018, then skyrocketed by 75.98% to $2.9 million in 2019, then skyrocketed by 452.51% to $16.2 million in 2020.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $16.2 million in Q4 2020, $11.6 million in Q3 2020, and $8.6 million in Q2 2020.